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Background: To investigate the 3.0-Tesla (3 T) magnetic resonance imaging (MRI) characteristics of primary adnexal
lesions for discriminating benign from malignant lesions.
Methods: One hundred thirty-nine patients with pathologically proven primary adnexal masses referred for 3 T MRI
assessment preoperatively were included. Baseline characteristics, components, and conventional MRI and
diffusion-weighted imaging (DWI-MRI) signals were recorded and compared.
Results: There were 22 ovarian cysts, 33 endometriomas, 43 benign tumors and 42 malignant tumors. When
ovarian cyst and endometrioma were excluded, there were no significant differences in patients’ age between
benign and malignant tumor (P = 0.235). There were no significant differences (P = 0.606) in the conventional MRI
signals and significant difference (P = 0.008) in DWI-MRI signal between the non-malignant and malignant lesions.
There was a significant difference (P = 0.000) in the apparent diffusion coefficient values (ADCs) between the
non-malignant and malignant lesions.
Conclusions: 3 T MRI categorized the characteristics of primary adnexal lesions. Conventional MRI signals were not
useful for characterizing between benign and malignant lesions. DWI-MRI and ADCs were helpful for distinguishing
malignant from benign ovarian lesions.
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The prevalence of adnexal masses in the general
population is 0.17%–5.9% in asymptomatic women
and 7.1%–12% in symptomatic women in the United
States [1]. Correct determination of the aetiology of
adnexal lesions before surgery may help in the choice
of optimal treatment and improve patient care by
avoiding aggressive therapy. Sonography is routinely
used clinically because of its low expense and easy
and rapid maneuverability. Nevertheless, its limited
capability of characterizing tissues makes it an unsuit-
able modality for complex adnexal masses and staging
of ovarian cancers [2]. With the advantages of superb
tissue contrast resolution and no ionizing radiation,* Correspondence: sh_radiology@yahoo.com.cn
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reproduction in any medium, provided the ormagnetic resonance imaging (MRI) is generally per-
formed for problem solving in the assessment of inde-
terminate sonographic adnexal masses [3-5] with a
sensitivity of 92% and specificity of 85% for the detection
of malignant adnexal tumors [1,5]. However, because of
the widely overlapping imaging characteristics of benign
and malignant ovarian tumors, even experienced gynae-
cological radiologists may have difficulty in making a
confident diagnosis before surgery [6]. With advance-
ments in MRI technology, diffusion-weighted imaging
(DWI-MRI) applied in gynaecological diseases also has
been reported in several studies with promising results
[7-9]. Compared with 1.5 T, the signal-to-noise ratio at
3 T has been increased and background suppression has
been improved, which allows better categorization of
variable components of ovarian diseases [10,11]. Studies
with focus on primary adnexal lesions evaluated by 3.0 T
(3 T) still are limited to date. The main purpose of thisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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MRI characteristics of primary adnexal lesions at 3 T and
compare with those of 1.5 T MR previously reported.
Methods
Study subjects
From Jan 2010 to Jun 2012, 312 consecutive patients with
clinically suspected adnexal diseases underwent 3.0 T MRI
examinations before pelvic or laparoscopic surgery. The
time interval between MRI evaluation and surgery was
within 1 month. Patients with metastatic ovarian tumors
(n = 32), recurrent diseases of known gynaecological malig-
nancies (n = 55), previous treatment history (n = 30) and a
lack of DWI-MRI (n = 3) were excluded. Patients with
mature teratoma (n = 53) were also arbitrarily excluded
because diagnosis is less challenging, as described in the
literature [9]. Therefore, we retrospectively reviewed 139
patients (13–83 years of age; average age, 51.3 ± 17.1 years)
with pathologically proven primary adnexal masses. The
patient cohort group included 22 ovarian cysts, 33 endome-
triomas and 43 benign and 42 malignant tumors. Details of
the patients are summarized in Table 1. Our institutional
review board approved this study, and waivers of informed
consent from all participants were granted.Table 1 The details of 140 primary adnexal lesions





Ovarian cyst 22 2.47 ± 0.93
Endometrioma 33 1.75 ± 0.71
Benign 43 2.03 ± 0.94
Brenner tumor 3 0.80 ± 0.22
Struma ovarii 4 2.58 ± 0.31
Fibroma 6 1.58 ± 1.09
Theca cell tumor 7 1.46 ± 0.50
Serous cystadenoma 9 2.51 ± 0.66
Mucinous cystadenoma 14 2.30 ± 1.02
Malignant 42 1.39 ± 0.62
Granular cell tumor 1 0.68
Embryonal carcinoma 1 1.31
Clear cell adenocarcinoma 5 1.25 ± 0.37
Endometrioid adenocarcinoma 5 1.06 ± 0.60
Leiomyosarcoma 1 0.86
Undefined adenocarcinoma 2 1.14 ± 0.41
Dysgerminoma 1 1.16
Mixed germ cell tumor 1 2.63
Serous cystadenocarcinoma 12 1.12 ± 0.42
Mucinous cystadenocarcinoma 4 2.11 ± 0.30
Borderline serous or mucinous
cystadenoma
9 1.90 ± 0.58
▲ indicates mean values ± standard deviation.Image acquisition
All MRI examinations were performed on a 3.0-Tesla
(3 T) system (Signa HD, General Medical Systems, GE,
USA) equipped with an 8-channel cardiac array coil.
The scan range was from the umbilicus level to the
pubic symphysis in the caudocranial direction. For any
larger lesion that could not be covered on axial imaging,
a sagittal scanning sequence was performed to include
as much of the entire lesion as possible. Routine MRI
protocols were used for the assessment of adnexal
masses, which included the following: axial fast spin-
echo (FSE) T1-weighted images (T1WI), sagittal FSE
T2WI and fat-suppressed T2WI (FS T2WI). A DWI-
MRI sequence used an echo-planar imaging sequence
with an array spatial sensitivity encoding technique. The
parameter details of the T1WI MR protocol were: repeti-
tion time (TR), 460 ms; echo time (TE), 10 ms; NEX, 2;
and thickness, 6.0 mm. The parameter details of the
T2WI MR protocol were: TR, 2400 ms; TE, 85 ms;
NEX, 1; and thickness, 6.0 mm. The parameter details of
the FS T2WI MR protocol were: TR, 3160 ms; TE,
90 ms; NEX, 2; and thickness, 6.0 mm. The parameter
details of the DWI-MRI MR protocol were: TR,
3500 ms; TE, 61 ms; NEX, 6; and thickness, 6.0 mm.
and, the b value = 0 and 700 s/mm2. A liver acquisition
with volume acceleration (LAVA) sequence was used to
perform contrast-enhanced pelvic imaging, and a power
injector (Missouri Ulrich; Ulm, Germany) was used for
injection of contrast material (Magnevist, Bayer Schering
Pharma AG, Germany). The parameter details of the
LAVA MR protocol were: TR, 3.4 ms; TE, 1.4 ms; NEX, 1;
flip angle, 1.5; and band width, 125 kHz. Images were
acquired at multiple phases of contrast medium enhance-
ment in both sagittal and axial planes (precontrast sagittal
and axial oblique and postcontrast at 20 seconds, 40 sec-
onds, 60 seconds and 80 seconds in the axial plane and
120 seconds in the sagittal plane).
MRI image analysis
The MRI characteristics of each adnexal lesion were
separately recorded according to the following items: 1)
lesion components graded on a 5-point scale [1 = cystic;
2 = solid; 3 = cyst with septum; 4 = cyst with solid
components (nodules); 5 = cyst with septum and solid
components; 2) signal intensity compared with that of
the outer myometrium on T1WI and T2WI graded on a
9-point scale (low or equal intensity on T1WI and high
intensity = 1, low intensity = 2 and mixed signal = 3 on
T2WI, high or equal intensity on T1WI and high inten-
sity = 4, low intensity = 5 and mixed signal = 6 on
T2WI, mixed signal on T1WI and low intensity = 7,
high intensity = 8, and mixed signal intensity = 9 on
T2WI) and 3) DWI-MRI signal graded on a 4-point
scale (1 = low; 2 = intermediate; 3 = high; 4 = mixed).
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of lesion were similar with the pelvic bone signal and
the intermediate signals were similar with the outer
myometrium. The high signals on DWI-MRI were like
that of endometrium.
Commercially available software was used on a postpro-
cessing workstation (GE Advantage workstation 4.3,
General Electric Healthcare, Milwaukee, WI, USA) to cal-
culate ADCs. Regions of interest (ROI) were drawn man-
ually in both cystic and solid areas with no more than 3
sites in each lesion on b value = 700 DWI-MRI images.
The round or elliptical circle were centrally placed in the
targeted region with the area range of 160–220 mm2. Only
the lowest ADCs were used for subsequent statistical
analysis. For any lesions which were not clearly depicted
on DWI-MRI, then axial fat-suppressed T2WI images and
dynamic contrast-enhanced images were also reviewed in
order to help to define the small nodular components.
ADCs were not available for small size (< 10 mm) in endo-
metric cyst group (one case) or severe pulsative artefacts
due to large size in benign tumors (three cases ≥ 100 mm)
and malignant tumors (four cases ≥ 250 mm).
Two observers (Y. Z. H. and H.Z, with 15 and 6 years of
experience in gynaecological imaging, respectively), who
were blinded to the histological results independently
analysed all of the MRI datasets of each participant on a
Picture Archiving and Communication System terminal
server. In patients with ≥ 1 lesions with different patho-
logical type, all lesions were selected for further analysis. For
interobserver discrepancies in the evaluation of adnexal
lesions, consensus was achieved or a majority decision was
obtained.Statistical analyses
Continuous variables were expressed as the means ±
standard deviation (SD) and compared with the un-
paired t-test if normally distributed or the Mann–
Whitney test if not normally distributed. A nonpara-
metric test (Mann–Whitney) was used to test the
components and signals of the lesions and the DWI-
MRI signal within each group. SPSS (version 13.0,
SPSS Inc., Chicago, USA) was used to perform statis-
tical analyses.Table 2 Baseline characteristics and ADC values of 139 patien
Histology diagnosis Numbers Age (year) Maximu
Ovarian cyst 21 52.2 ± 15.3 58.9 ± 3
Endometrioma 33 37.0 ± 10.4 49.2 ± 2
Benign tumor 43 58.8 ± 17.1 82.1 ± 5
Malignant tumor 42 54.5 ± 16.0 108.6 ±
* CA125 values were not unavailable in 31 cases.
▲ indicates mean values ± standard deviation.Results and discussion
In these 140 samples, the mean patient age in the endo-
metrioma group was lower than that in the other
groups. The patients’ mean age and maximum diameter
of the lesions in the endometrioma group differed
significantly with the benign and malignant ovarian
tumors. In the ovarian cyst group, the mean age was sig-
nificantly different from that of the endometrioma group
(P = 0.000) but did not differ from that of the other
groups. The maximum diameter of the ovarian cyst was
similar to that of the endometrioma (P = 0.172), smaller
than that of the benign lesions (P = 0.032) and much
smaller than that of the malignant lesions (P = 0.000).
When ovarian cyst and endometrioma were excluded,
there were no significant differences in age between the
benign and malignant tumors (P = 0.235). The CA125
level in the ovarian cyst group was obviously less than
that in the other groups. The CA125 level in the endome-
trioma group was higher than that in the benign tumor
group (P = 0.000) and less than that in the malignant
group, but the difference was not significant (P = 0.400).
When endometriomas were excluded, there was still a
significant difference in the CA125 level between the
benign and malignant tumors (P = 0.000). The basic char-
acteristics of the studied patients are summarized in Table 2
and Table 3.Conventional MRI lesions appearance
Most of ovarian cyst (18/22) (Figure 1) and endometrioma
(27/33) appeared as cystic lesions. Most of the benign
tumors appeared as lesions that were solid (14/43) or cyst
with septa (14/43). A cystic component combined with a
solid nodule (22/42) was the most common type in the
malignant group. There were 15 solid lesions in benign and
7 solid lesions in malignant group (Figure 2). There was
significant difference in signal between the benign and
malignant tumor (P = 0.000). The MRI components within
the 4 groups in 140 primary adnexal lesions are summar-
ized in Table 4.Conventional MRI signal character
Most of ovarian cyst (13/22) showed as low/equal in-
tensity on T1WI and mixed signal on T2WI. Most ofts with pathologically proven primary adnexal masses
m Diameters (mm) CA125* ADC (10-3/mm2/s)▲
1.2 36.3 ± 51.2 2.47 ± 0.93
0.4 78.5 ± 91.6 1.75 ± 0.71
4.1 42.4 ± 88.0 2.03 ± 0.94
57.2 310.4 ± 745.4 1.39 ± 0.62
Table 3 The statistically significant difference (p value) of baseline characteristics and ADC values within four groups
in 139 patients with pathologically proven primary adnexal masses
Age* Maximum Diameters* CA125▲level (U/mL) ADC* (10-3/mm2/s)
Ovarian cyst & Endometrioma 0.000 0.211 0.001 0.003
Ovarian cyst & Benign tumor 0.119 0.032 0.509 0.080
Ovarian cyst & Malignant tumor 0.570 0.000 0.001 0.000
Endometrioma & Benign tumor 0.000 0.001 0.000 0.121
Endometrioma & Malignant tumor 0.000 0.000 0.400 0.032
Benign group & Malignant group 0.235 0.031 0.000 0.000
Non-malignant & Malignant 0.065 0.000 0.000 0.000
* Unpaired t-test was used to test the significant difference.
▲ Mann–Whitney test was used to test the significant difference.
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sity on T1WI and hyper intensity on T2WI. Accord-
ingly, most of the benign (29/43) and malignant
tumors (19/42) showed low/equal intensity on T1WI
and hyper intensity on T2WI. The MRI signals between
ovarian cyst and endometrioma and benign tumor gave
statistically significant differences (P = 0.000, P = 0.000),
while no difference was observed between ovarian cyst and
malignant tumor (P = 0.965). There was a significant differ-
ence between the endometrioma and benign and malignant
tumor (P = 0.000, P = 0.002). The signal difference betweenFigure 1 A 60-year-old female patient with histological proven hemo
mass with mostly isointensity in the right adnexal region. (b) On sagital T2
while the debris of hemorrhagic components are iso-hypo intensity, morph
T2WI, the signal of mass is similar with (b). (d) The lesion shows weakly, ma
On DWI-MRI (b = 700 s/mm2), the lesion upwardly appears as the homoge
(f) ADC map demonstrates marked hyperintensity of the cystic component
ADC values at the corresponding site are 2.59 ×10-3 (cyst) and 1.76 ×10-3 (sbenign and malignant tumor also significantly differed (P =
0.008). The MRI signals of the lesions were not significantly
different between the non-malignant (regarding the ovarian
cyst, endometrioma and benign ovarian tumor as the whole
category) and malignant lesions (P = 0.606). The MRI signal
characteristics within the 4 groups are summarized in
Table 5.
DWI-MRI character
Most of the primary adnexal lesions (69/140) showed
hyperintensity on DWI-MRI. Most of the malignantrrhagic ovarian cyst. (a) Axial T1WI reveals an inhomogeneous cystic
WI, the cystic component of the tumor is homogenous hyperintensity,
ologically mimicking vegetations on the wall. (c) On fat-suppressed
rginally enhancement on contrast-enhanced fat-suppressed T1WI. (e)
neous hyperintensity and downwardly as inhomogenous isointensity.
s (T2 shine-through effect) and isointensity of solid components. The
olid), respectively.
Figure 2 A 60-year-old female patient with Granular cell tumor. (a) Axial T1WI reveals a well-demarcated solid tumor with hyperintensity in
the left adnexal region. (b) On fat-suppressed T2WI, the mass shows mixed hyperintensity. (c) On DWI-MRI (b = 700 s/mm2), the lesion appears as
the inhomogeneous hyperintensity. (d) ADC map demonstrates marked hypointensity of the solid components. The ADC value at the
corresponding site is 0.68x10-3.
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ences in DWI-MRI signals within each group were sta-
tistically significant except between endometrioma and
malignant tumor (P = 0.546). However, the DWI-MRI
signals of the lesions were significantly different between
the non-malignant and malignant groups (P = 0.008).
The DWI-MRI signals within the 4 groups are summar-
ized in Table 6.
In our results, the highest ADC value was 2.47 ± 0.93
observed in ovarian cyst, while the lowest was 1.39 ± 0.62
in the malignant tumor (Table 1). The mean ADC value of
ovarian cysts was higher than that of the other groups,
although a significant difference between the ovarian cystTable 4 The MRI components within four groups in 140 prim




Eendometrioma 27 1 4
Benign tumor 8 14 14
Malignant tumor 2 7 2
Total 55 22 20and benign tumors was not observed (P = 0.080). No
significant differences were observed in the ADCs between
the endometrioma and benign (P = 0.121), but a significant
difference was observed between the benign and malignant
tumor (P = 0.000) (Figure 3). There was also a significant
difference between the non-malignant and malignant
lesions (P = 0.000). In the 22 solid lesions in this sample
(Figure 2), the mean ADCs between the benign and malig-
nant tumors were not significantly different (P = 0.399).
Primary adnexal masses comprise a broad spectrum of
diseases in which the aetiology is often difficult to deter-
mine by ultrasonography because of the similarity in the
















Table 5 The MRI signal characteristics within four groups in 140 primary adnexal lesions
T1WI Low and/Equal intensity T1WI High and/Equal intensity T1WI Mixed intensity Total
T2WI Pathology Type Hyper Hypo Mixed Hyper Hypo Mixed Hyper Hypo Mixed
Ovarian cyst 4 3 13 2 22
Endometrioma 3 2 17 7 2 2 33
Benign tumor 29 8 5 1 43
Malignant tumor 19 4 13 1 5 42
Total 55 17 13 37 7 3 8 140
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for distinguishing benign from malignant ovarian tumors
[12-16].
We reported our single-centre preliminary experiences
using 3.0 T MRI for evaluation of primary adnexal
lesions in 139 subjects. With respect to baseline charac-
teristics of primary adnexal lesions, when ovarian cyst
and endometrioma were excluded, there was significant
difference in maximum diameters of lesions and CA125
level between the primary ovarian benign and malignant
tumors. CA125 level could be used as a reference stan-
dard for differentiating benign from malignant tumors
[17], although some overlap between endometrioma and
malignant tumors was observed.
Considering the components of lesions, our findings
are in line with those of other studies that used conven-
tional imaging and showed that complex structures were
more often seen in ovarian tumors and there was more
overlap in appearance between benign and malignant
tumors [2,18-21]. In our series, except for ovarian cyst,
the signal intensity in all primary ovarian lesions varied
considerably, which would present a diagnostic challenge
if conventional imaging only were used. The typical
shading character (high signal on T1WI and low signal
on T2WI) of endometrioma, as well described in the
literature [22], does not often occur in this patient
group. It has been reported that endometriosis is a
precursor lesion of ovarian malignancies, particularly in
endometrioid and clear-cell types [2,23]. Considering
this, caution is needed to precisely confirm the diagnosis
of endometrioma, especially in cases with atypical
imaging findings.Table 6 The DWI signals within four groups in 140
primary adnexal lesions
Pathology Type Low Intermediate High Mixed Total
Ovarian cyst 12 3 4 3 22
Endometrioma 3 20 10 33
Benign tumor 6 14 18 5 43
Malignant tumor 1 4 27 10 42
Total 22 21 69 28 140DWI-MRI is a functional imaging technique that is
now widely applied for characterization of primary
adnexal lesions and staging of ovary cancers [7,9,24,25].
However, DWI-MRI in gynaecological adnexial masses
must be carefully interpreted by diagnosticians because
any normal structures could appear bright on high
b-value images [26,27]. Two studies reported that the
areas of high signal intensity on DWI-MRI were
observed more often in malignant than in benign tumors
[7,28]. In another study, the author concluded that the
DWI-MRI signal was more related to the signal intensity
of the fluid rather than to a histopathological component
[29]. In our study, except for ovarian cyst, most parts of
the primary adnexal lesions showed high signals on
b = 700 DWI-MRI in both benign and malignant
tumors. On the whole, there was significant difference in
the DWI-MRI signal between non-malignant and malig-
nant lesions, a finding that is inconsistent with that of a
study by Fujii S et al. [30]. The possible explanation is
that in their study, teratoma was included, which was
different with our studied samples, may result in
elevated numbers with high DWI-MRI signal in benign
group. In one article, investigators stated that low T2
signal and low signal on DWI-MRI with a b-value of
1000 were the best criteria for predicting benignity [9].
However, we do not support this point of view. In our
data, we found that few lesions with these characteristics
were encountered, which would lead to limited applica-
tion in a clinical situation.
In theory, as a result of high cell densities and abun-
dant cellular membranes, the ADCs should be generally
lower in cancerous tissue than in noncancerous tissue
[8]. Even so, the application of ADCs in differentiating
malignant from benign ovarian tumors remains a
controversy [9,28-32]. The choice of b-values, varying
pathologies and the number of studied samples all result
in a wide divergence of reported ADCs for ovarian cystic
and solid diseases. In our results, the highest ADC value
was 2.47 ± 0.93 observed in ovarian cyst, while the
lowest was 1.39 ± 0.62 in the malignant group. It is
worth noting that the wide range of calculated ADCs in
the benign group resulted in considerable overlap with
those of the endometrioma and malignant tumor,
Figure 3 Stem-and-Leaf Plots of the calculated ADC values (10-
3/mm2/s) within four groups. The mean ADC values in ovarian
cysts were higher than that in other three groups. The mean ADC
values in benign tumor were obviously higher than that in
malignant tumor (p = 0.000), while wide overlaps with
endometrioma (p = 0.121).
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between the benign and malignant tumor (P = 0.000).
This phenomenon reflects the more variable compo-
nents of benign ovarian tumors. We excluded teratomas
from further analysis because these lesions can be easily
detected without any diagnostic challenge [9,21,29].
Thomassin NI et al. reported that the ADCs of the cystic
component and of the solid component did not differ
between malignant and benign adnexal masses [9]. How-
ever, in their study, the benign groups with measurable
solid component ADCs mainly composed of rich colla-
gen fibril cells obviously restricted the diffusion of water
molecules and resulted in low ADCs, which was differ-
ent with our study. In another study, the authors also
declared that ADCs may not provide additional informa-
tion for differentiating between benign and malignant
tumors [29]. However, there were only 10 malignant
cases in their research, which considerably limited the
broader applicability of their conclusions. In addition,
ovarian metastatic tumors were excluded in our patient
selection, which is mostly different from the selection
used in other reported studies [9,28-32]; therefore, our
study sample may more accurately reflect the true
features of ovarian masses.
We agree with the view of Takeuchi M et al. that some
benign fibrous lesions also have lower ADCs with, ironi-
cally, no elevated signal on DWI-MRI [28]. However, the
typical character of the low signal on T2WI allows easy
differentiation of these benign lesions from malignant
tumors. Considering the 22 solid lesions, however, differ-
ences in ADCs between benign and malignant types were
not observed in this study. Bakir B et al. studied 37 patientswith solid or predominantly solid adnexial masses who
underwent DWI-MRI evaluation and disclosed that the
ADCs of both malignant and benign adnexal lesions also
did not show a significant difference [7]. To date, DWI-
MRI and ADC evaluations of ovarian solid tumors have
not been fully investigated. Because of the relatively small
samples, these results are conservative and need to be
verified in a large study.
We must acknowledge several limitations in our study.
First, some authors have recommended that any lesion dis-
playing a high T1 signal before the DWI sequence should
be excluded to limit T1 contamination because the ADC
value may increase linearly with decreasing protein concen-
trations [9,33]. In this study, we did not exclude these
lesions so that we could encompass different types of
lesions as much as possible. However, we do think this
influenced the DWI-MRI signal, which could not show the
real restricted diffusion of the lesions. Second, the area of
the ROI on which the ADCs were calculated was manually
outlined. Lack of standardization in selecting ROI areas also
may influence the final ADCs. Third, in our study, we
compared our results using 3 T MRI with those of other
studies that used 1.5 T MRI. Although Takeuchi M et al.
reported that there was no significant difference between
the ADC values obtained at 1.5 T and 3.0 T [28], a direct
comparison between the two modalities may be still needed
to clarify the true difference in ADC s.Conclusions
The results of our investigation of 3.0 T MRI revealed
that there were no significant differences in MRI signals
between benign and malignant lesions. Pure cystic
masses are more often observed in benign tumors, while
cystic and solid tumors are more common in malignant
tumors, as previously reported. DWI-MRI signal and
ADCs are useful for discriminating between benign and
malignant tumors because the latter show much lower
ADC values and high signal on DWI.Competing interest
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